Bank of America Corp vs Sanofi SA — how do they compare? Bank of America Corp trades at $64 (market cap $447.54B), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: Bank of America Corp is far larger — about 4.3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| BAC | SNY | |
|---|---|---|
Market Cap | $447.54B | $104.30B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $52.34 |
52-Week Low | $46.72 | $41.33 |
Dividend Yield | 2% | 5.55% |
Enterprise Value | — | $124.19B |
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $63.86, up 1.09% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and revenue growth to $113.10B in 2025. Analyst consensus is strongly positive, with a $67.36 price target and 35 buy ratings. Recent news highlights strategic partnerships and hiring initiatives, reinforcing growth prospects.
BAC presents a favorable investment opportunity driven by earnings beats, robust deposit franchise, and potential capital returns post-stress tests. Risks include interest rate sensitivity and macroeconomic volatility. The stock's current valuation at a P/E of 14.78 offers room for upside relative to historical averages, supported by institutional bullishness.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →